Niosomal And Ethosomal Gels: A Comparative In Vitro And Ex Vivo Evaluation For Repurposing Of Spironolactone

This study explored the development of polymeric nanoparticles for topical spironolactone delivery, finding that larger nanoparticles (180 nm) enhanced drug targeting to hair follicles significantly more than smaller ones or non-nanoparticle formulations, offering promise for safer acne and alopecia treatments.

This study suggests that a microemulsion formulation of Minoxidil effectively enhances drug delivery through hair follicles, showing significant follicular response alterations in an alopecia model.

In this study, spironolactone was reported to stabilize or improve female pattern hair loss in 74.3% of treated women, especially those with signs of hyperandrogenism.

This study suggests that spironolactone-loaded nanostructured lipid carriers could enhance follicular delivery and offer a more localized treatment for androgenic alopecia, potentially reducing systemic side effects.

This study found that minoxidil-loaded niosomes with a Span 60 and cholesterol ratio of 1:2 significantly increased skin retention of minoxidil compared to control gel.

In this study, niosomal formulations enhanced minoxidil skin accumulation compared to commercial and control solutions, suggesting a potential improvement for topical delivery in hair loss treatment.

This study found that 88% of women with female pattern hair loss who received oral antiandrogens saw no progression or improvement in their condition.

Topical spironolactone effectively treats hair loss in women.